Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Proceeds from (Payments to) Noncontrolling Interests

2.8 / 5 stars · 68/120 Roast Me

GILEAD SCIENCES, INC. Proceeds from (Payments to) Noncontrolling Interests

GILEAD SCIENCES, INC. (GILD) reported Proceeds from (Payments to) Noncontrolling Interests of -$90.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-27.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromPaymentsToMinorityShareholders · last filed 2017-02-27

  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2016-12-31 was -$7.00M, a 114.89% decline year-over-year.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2016-09-30 was -$82.00M, a 142.93% decline year-over-year.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2016-06-30 was -$42.00M.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for the quarter ending 2016-03-31 was $41.00M, a 105.00% increase year-over-year.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for fiscal 2016 was -$90.00M, a 147.87% decline from fiscal 2015.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for fiscal 2015 was $188.00M, a 437.14% increase from fiscal 2014.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for fiscal 2014 was $35.00M, a 76.97% decline from fiscal 2013.
  • GILEAD SCIENCES, INC. proceeds from (payments to) noncontrolling interests for fiscal 2013 was $152.00M, a 16.03% increase from fiscal 2012.
Period endProceeds from (Payments to) Noncontrolling Interests 3 monthProceeds from (Payments to) Noncontrolling Interests 3 month as first filedProceeds from (Payments to) Noncontrolling Interests 6 monthProceeds from (Payments to) Noncontrolling Interests 6 month as first filedProceeds from (Payments to) Noncontrolling Interests 9 monthProceeds from (Payments to) Noncontrolling Interests 9 month as first filedProceeds from (Payments to) Noncontrolling Interests 12 monthProceeds from (Payments to) Noncontrolling Interests 12 month as first filed
2016-12-31-$7.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
-$89.00M
derived: sum of 2 quarters · filed 2017-02-27
-$131.00M
derived: sum of 3 quarters · filed 2017-02-27
-$90.00M
10-K · filed 2017-02-27
2016-09-30-$82.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
-$124.00M
derived: sum of 2 quarters · filed 2016-11-07
-$83.00M
10-Q · filed 2016-11-07
-$36.00M
derived: sum of 4 quarters · filed 2017-02-27
2016-06-30-$42.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
-$1.00M
10-Q · filed 2016-08-05
$46.00M
derived: sum of 3 quarters · filed 2017-02-27
$237.00M
derived: sum of 4 quarters · filed 2017-02-27
2016-03-31$41.00M
10-Q · filed 2016-05-06
$88.00M
derived: sum of 2 quarters · filed 2017-02-27
$279.00M
derived: sum of 3 quarters · filed 2017-02-27
$209.00M
derived: sum of 4 quarters · filed 2017-02-27
2015-12-31$47.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$238.00M
derived: sum of 2 quarters · filed 2017-02-27
$168.00M
derived: sum of 3 quarters · filed 2017-02-27
$188.00M
10-K · filed 2017-02-27
2015-09-30$191.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07
$121.00M
derived: sum of 2 quarters · filed 2016-11-07
$141.00M
10-Q · filed 2016-11-07
$237.00M
derived: sum of 4 quarters · filed 2017-02-27
2015-06-30-$70.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05
-$50.00M
10-Q · filed 2016-08-05
$46.00M
derived: sum of 3 quarters · filed 2017-02-27
$12.00M
derived: sum of 4 quarters · filed 2017-02-27
2015-03-31$20.00M
10-Q · filed 2016-05-06
$116.00M
derived: sum of 2 quarters · filed 2017-02-27
$82.00M
derived: sum of 3 quarters · filed 2017-02-27
$111.00M
derived: sum of 4 quarters · filed 2017-02-27
2014-12-31$96.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27
$62.00M
derived: sum of 2 quarters · filed 2017-02-27
$91.00M
derived: sum of 3 quarters · filed 2017-02-27
$35.00M
10-K · filed 2017-02-27
2014-09-30-$34.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04
-$5.00M
derived: sum of 2 quarters · filed 2015-11-04
-$61.00M
10-Q · filed 2015-11-04
-$61.10M
10-Q · filed 2014-11-05
$10.41M
derived: sum of 4 quarters · filed 2016-02-24
2014-06-30$29.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05
-$27.00M
10-Q · filed 2015-08-05
-$26.79M
10-Q · filed 2014-08-04
$44.41M
derived: sum of 3 quarters · filed 2016-02-24
$105.28M
derived: sum of 4 quarters · filed 2016-02-24
2014-03-31-$56.00M
10-Q · filed 2015-05-08
-$55.74M
10-Q · filed 2014-05-07
$15.41M
derived: sum of 2 quarters · filed 2016-02-24
$76.28M
derived: sum of 3 quarters · filed 2016-02-24
$92.41M
derived: sum of 4 quarters · filed 2016-02-24
2013-12-31$71.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-24
$132.28M
derived: sum of 2 quarters · filed 2016-02-24
$148.41M
derived: sum of 3 quarters · filed 2016-02-24
$152.00M
10-K · filed 2016-02-24
$151.83M
10-K · filed 2014-02-25
2013-09-30$60.87M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05
$77.00M
derived: sum of 2 quarters · filed 2014-11-05
$80.59M
10-Q · filed 2014-11-05
$179.17M
derived: sum of 4 quarters · filed 2015-02-25
2013-06-30$16.13M
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04
$19.72M
10-Q · filed 2014-08-04
$118.30M
derived: sum of 3 quarters · filed 2015-02-25
$188.03M
derived: sum of 4 quarters · filed 2015-02-25
2013-03-31$3.59M
10-Q · filed 2014-05-07
$102.18M
derived: sum of 2 quarters · filed 2015-02-25
$171.90M
derived: sum of 3 quarters · filed 2015-02-25
$208.18M
derived: sum of 4 quarters · filed 2015-02-25
2012-12-31$98.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-25
$168.31M
derived: sum of 2 quarters · filed 2015-02-25
$204.59M
derived: sum of 3 quarters · filed 2015-02-25
$131.00M
10-K · filed 2015-02-25
$130.60M
10-K · filed 2013-02-27
2012-09-30$69.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-31
$106.01M
derived: sum of 2 quarters · filed 2013-10-31
$32.41M
10-Q · filed 2013-10-31
$47.85M
derived: sum of 4 quarters · filed 2014-02-25
2012-06-30$36.28M
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-01
-$37.31M
10-Q · filed 2013-08-01
-$21.87M
derived: sum of 3 quarters · filed 2014-02-25
-$66.33M
derived: sum of 4 quarters · filed 2014-02-25
2012-03-31-$73.59M
10-Q · filed 2013-05-08
-$58.16M
derived: sum of 2 quarters · filed 2014-02-25
-$102.62M
derived: sum of 3 quarters · filed 2014-02-25
-$163.47M
derived: sum of 4 quarters · filed 2014-02-25
2011-12-31$15.44M
derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25
-$29.02M
derived: sum of 2 quarters · filed 2014-02-25
-$89.88M
derived: sum of 3 quarters · filed 2014-02-25
-$115.04M
10-K · filed 2014-02-25
2011-09-30-$44.46M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
-$105.31M
derived: sum of 2 quarters · filed 2012-11-06
-$130.47M
10-Q · filed 2012-11-06
-$41.77M
derived: sum of 4 quarters · filed 2013-02-27
2011-06-30-$60.85M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01
-$86.02M
10-Q · filed 2012-08-01
$2.69M
derived: sum of 3 quarters · filed 2013-02-27
$40.35M
derived: sum of 4 quarters · filed 2013-02-27
2011-03-31-$25.16M
10-Q · filed 2012-05-04
$63.54M
derived: sum of 2 quarters · filed 2013-02-27
$101.21M
derived: sum of 3 quarters · filed 2013-02-27
$80.97M
derived: sum of 4 quarters · filed 2013-02-27
2010-12-31$88.70M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27
$126.37M
derived: sum of 2 quarters · filed 2013-02-27
$106.13M
derived: sum of 3 quarters · filed 2013-02-27
$131.52M
10-K · filed 2013-02-27
2010-09-30$37.67M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-04
$17.43M
derived: sum of 2 quarters · filed 2011-11-04
$42.82M
10-Q · filed 2011-11-04
2010-06-30-$20.24M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-05
$5.15M
10-Q · filed 2011-08-05
2010-03-31$25.39M
10-Q · filed 2011-05-09
2009-12-31-$44.75M
10-K · filed 2012-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31